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HIV and hepatitis virus infections among
injecting drug users in a medically controlled
heroin prescription programme
THOMAS STEFFEN, RICHARD BLATTLER, FELIX GUTZWILLER, MARCEL ZWAHLEN *
Background: In Switzerland, 1,035 patients were accepted for admission to the medically controlled prescription of
narcotics programme (PROVE) from 1 January 1994 until 31 December 1996. Heroin, methadone, and morphine
were prescribed. This paper presents the prevalence and incidence of HIV and hepatitis B/C infections in the
sociomedical context of the participants. Methods: Admission criteria were a minimum age of 20 years, at least a
two-year duration of daily heroin consumption, a negative outcome of at least two previous treatments, and
documented social and health deficits as a consequence of their heroin dependence. The patients were examined at
admission and every six months. A serological test was carried out at the same time for HIV and hepatitis B/C.
Results: Serological testing on admission could be performed in more than 80% of the entrants and documented a
very high seroprevalence of antibodies against HBCOre (73%) and HCV (82%). The prevalence of HIV and hepatitis
B/C increased with duration of drug intake. In the follow-up analysis of seronegative individuals, a halving of the
risk of viral hepatitis infection was shown when comparing the first six months with the period greater then six
months after PROVE entry. Conclusion: The tests conducted showed high prevalence and incidence rates of HIV and
hepatitis B/C among patients who had consumed intravenous drugs for years. The descriptive analysis in
heroin-assisted treatment showed a reduction in infection risk for viral hepatitis corresponding to the lower risk
behaviour of patients.
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T,he number of drug users in Switzerland who consume
opiate and cocaine was estimated at the outset of the
1990s at about 30,000 people, representing about 0.6% of
the population between 15 and 39 years of age.1
Serious individual health and social problems are often
linked with this drug use for example evidenced in a
limited social network, an increased delinquency, and in
poor housing and job conditions.2 The prevalence of
various somatic and psychological ailments was shown to
be substantial among intravenous drug consumers.-'"-'
Infections with hepatitis B, hepatitis C and Human
immunodeficiency virus (HBV, HCV and HIV) among
drug addicts are epidemic.6'7 In Switzerland about 40% of
all newly reported AIDS cases during 1996 were among
drug-injecting people. It is estimated that each fifth HIV
infection occurred among a drug-injecting person. More
than 40% of all registered hepatitis B infections and about
60% of registered hepatitis C infections are accounted for
today by intravenous drug users.8"10
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Since the 1980s various interventions have aimed to
improve the situation of drug addicts in Switzerland.
Additionally, a great variety of therapeutic measures have
been established to treat opiate-dependent patients in
Switzerland. About 1,700 stationary treatment slots are
available for addiction withdrawal. Since 1997, roughly
15,000 patients have received methadone within the
framework of maintenance treatments.
Despite the availability of a wide range of treatment
programmes, not all drug addicts with serious health and
social problems could be motivated to enter treatment.
This core group is characterized by numerous social and
medical deficiencies.
In an attempt to reach more drug users, 800 slots for
heroin prescription were provided in 1994-1996 within
the framework of a programme for medically prescribed
narcotics. Based on the experience from therapy with oral
methadone, it was argued that drug users who could not
be treated sufficiently in the past might be reached with
such new treatment forms.12"14
As mentioned, the epidemic of HIV infection in the
1980s as well as the continuing risk of hepatitis B and C
infections was one reason for considering heroin-assisted
treatment programmes in addition to other treatment
options. Current HIV and hepatitis transmission data was
collected within the framework of this programme.
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Correlations related to the medical and social situation of
intravenous drug users could be analysed more closely to
built the basic for new evidence-based interventions. In
addition, the question arises, can a medically controlled
heroin prescription programme lower the rate of new
infections by the reduction of risk behaviour? This article
shows a descriptive analysis of the HIV and hepatitis B/C
infections in individuals in the heroin-assisted treatment
programme in Switzerland during 1994-1996.
METHODS
Patients
In Switzerland from the beginning of 1994 to 30 June
1996, 1,146 individuals entered the treatment pro-
gramme for medical prescription of narcotics (PROVE).
Of these, 1,035 were accepted for admission to the cohort
study.12 One hundred and eleven participants were
disqualified for the following reasons: 84 left treatment
before completing the admission test, and 27 failed to
fulfil the inclusion criteria. The patients were admitted to
18 project centres in mainly urban areas. Women com-
prised 30% of those admitted to treatment. The average
age at admission was 30.8 (SD 5.7) years.
Assessments
The study was approved by the federal government and
was restricted to drug addicted patients who had not been
treated sufficiently and successfully in the past. The de-
tails of the study design are described elsewhere.12 Briefly,
the patients entering the study had to fulfil the following
criteria:
• a minimum age of 20;
• at least two years of opiate dependence (injecting drug
users);
• at least two unsuccessful treatment attempts;
• documented deficiencies in a medical and/or social area.
Fulfilment of the admission criteria were recorded for
each patient before the onset of treatment. The indica-
tion for treatment was determined by an experienced
physician based on the current anamnesis, current results
of medical testing, and the medical record. The indication
was reviewed by two independent offices for each case.
Social and medical data
The social data were gathered by standardized interviews
carried out by trained interviewers. The questionnaires
were consistent with the EuropASI.15
Upon admission and every six months thereafter study
participants were scheduled for thorough medical exam-
inations by attending physicians. There, the somatic and
psychological status of patients was recorded in stand-
ardized form. Additionally, patients were tested for HIV
and hepatitis B and C. Serological testing upon admission
was performed in more than 80% of study entrants (HIV:
87%, hepatitis B: 83%, hepatitis C: 83%). It is noteworthy
that 64% of study entrants who were not tested for HIV
were HIV positive according to anamnestic data. Fre-
quent reasons for failure to conduct the serological test
iM during the course were difficulties in taking blood samples
among long-term I.V. drug users and patient refusal. The
following tables each indicate missing data (md).
An anti-HIV test was carried out during the serological
examination including Western Blot analysis for con-
firmation of positive test, according to the Swiss HIV test
recommendations.
Serological examinations were also carried out in keeping
with the study protocol to determine the hepatitis B and
C rates. For hepatitis B virus the presence of the anti-HBc
igG was determined. For hepatitis C virus the anti-HCV
antibodies was determined.
Treatment
Treatment was determined according to individual
indications. Heroin was usually prescribed as were
methadone and morphine (daily average dose of heroin
i.v., 471 mg; methadone i.v., 87 mg; morphine i.v.,
442 mg). Application normally occurred intravenously
and orally. Patients received intensive social medicine
monitoring at the project centres. Study participants were
given regular medical examinations and were treated
somatically and emotionally. Social assistance was
offered. Of the 100 patients, an average of 6.6 gained
full-time jobs (social work, 2.0 jobs; medical service, 1.8;
administration, 1.65; dispensing team, 0.75; other
services, 0.4).
Statistical analyses
Chi, Phi, and Cramer's V tests were used to analyse
differences between groups. A p-value of 0.05 or less was
considered statistically significant. The SPSS statistical
programme and Epilnfo 6.0 were used for statistical cal-
culations.16'17
Calculations of incidence were based on patients with a
negative laboratory finding at the start of each six months
interval. Patients with a seroconversion during treatment
were disqualified for follow-up incidence calculations. In
the case of missing laboratory findings, the patient was
not considered in incidence calculations for the periods
involved.
Also taken into consideration were those leaving the
programme prematurely and those not remaining long
enough to have had a next follow-up visit with serological
tests. The six-month incidence was calculated in the
following way. The numerator was the number of new
infectious diagnosed between follow-up visit Ti and
Tj+j.The denominator was the sum of the new infections
(between T; and T,+i) and all those individuals who were
followed up to follow-visit at Ti+i. For example, the HIV
incidence in the first six months was calculated as
5/(557+5) (table 3). The relative risk comparing the first
six months with the period greater than six months was
calculated by pooling the later periods.
Confidence intervals (95%) and p-values for the relative
risk calculations were obtained from Epiinfo 6.0.
RESULTS
Table I shows the social characteristics of all patients
newly admitted to treatment. Some 70% of the
HJV and hepatitis virus infections
participants were men. On average the patients had
consumed heroin for 10.5 years (SD 5.5). On admission
the participants' average age was about 31 years. Only
16% of admissions had a regular job. The housing
situation was unstable for about half, and 13% were
homeless. Half of the patients indicated having income
from illegal activities.
According to the serological test, 15% of patients were
HIV positive on admission, while 73% had hepatitis B
antibodies (anti-HBCOre), and 82% had hepatitis C
antibodies (table 2). Only 11% of admissions were
negative for HIV as well as hepatitis B and C, and 13%
had a positive test result for all three pathogens. More men
than women tested positive for hepatitis B on admission.
No gender difference was observed for HIV and HCV.
The prevalence of all three pathogens increased with
increasing duration of use. Among patients with
addiction surpassing 15 years, almost all had hepatitis C
antibodies.
During the follow-up, 52 seroconversions were observed
among 50 patients within the treatment cohort group. Of
those 30 seroconversions appeared during the first six
months of treatment, and 22 new infections in the follow-
ing months of treatment.
Tables 3-5 show the number of newly diagnosed HIV and
hepatitis B/C infections during the first 30 months of
treatment.
Table 1 Social characteristics of patients on admission in the
Swiss medically controlled prescription of narcotics programme
1994-1996 (n=l,035)
During the observation period a total of 11 HIV sero-
conversions were diagnosed (table 3), five in the first six
months. The incidence rate during the first 18 months
of treatment was 1% per half year (follow-up periods).
There was no significant reduction in infection risk
between the first period (six-month laboratory tests) and
later laboratory periods.
There were 22 newly diagnosed hepatitis B and 19 new
hepatitis C infections during treatment (tables 4 and 5).
In the first six months of treatment for both hepatitis B
and C, the estimated incidence was 10% per half year.
The risk of a hepatitis infection (B or C) was halved
during the course of treatment (relative risk 0.51 [0.28-
0.93] p<0.05), when comparing the first six months of
follow-up to the subsequent follow-up periods. This risk
reduction was also observed for HCV infections.
Table 6 shows the patients' important characteristics with
and without new infections. A direct assessment of
incidence in the subgroups is not possible because of the
two cohort groups' varying susceptibility.
The comparison of patients with and without seroconver-
sion showed no gender differences (table 6). In accord
with the lower prevalence on admission, more serocon-
versions occurred among patients who had been opiate-
addicted for only a few years. More new infections were
tallied among patients with a less favourable social situ-
ation (illegal income) and regular cocaine consumption.
DISCUSSION
In keeping with admission criteria, 1,035 opiate addicts
Social characteristics
Gender
Male
Female
Age (years)
Mean age
<25
26-35
>35
Housing
Stable housing situation
Unstable housing situation
Friendships
No close friends
Close friends primarily in the drug scene
Close friends primarily outside the drug scene
Work
Regular work
Temporary, allowance, housework
Unemployed
Criminal behaviour
Illegal income
Drug consumption
Almost daily heroin use
Almost daily cocaine use
Average duration of heroin use
%
70
30
31 years
19
61
20
51
49
30
30
41
16
42
42
50
81
30
10.5 years
(SD5.5)
for the 1994-1996 cohort study on heroin-assisted treat-
ment. The admission situation
tion is not representative of all
described in this popula-
of drug addicts in Switzer-
land. Instead the data given represent the
Table 2 Seroprevalence at admission
living situation
i by gender and duration
of heroin use (n=l,035) in the Swiss medically controlled
prescription of narcotics programme
HIV
positive
0/70
All patients" 15
n=138
md=136 t
Gender
Male 15
Female 16
p-value n.s.
Duration of
heroin use
2—4 years 3
5-9 years 9
10-15 years 22
>15 years 25
p-value15 p<0.001
1994-1996
Hepatitis B
positive
0//o
73
n=625
nd=181
75
68
p<0.05
47
69
79
87
p<0.001
Hepatitis C
positive
0//o
82
n=706
md=176
82
82
n.s.
55
76
90
98
p<0.001
a: 136, 181, and 176 patients were not tested at entry for HIV, HBV,
and HCV.
b. Phi / Cramer's V test.
md: missing data
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of long-term opiate addicts who previously lacked access
to successful forms of treatment.
Serological data on more than 80% of the patients were
available at admission. Not all patients could be
examined every six months, even during course testing.
Table 3 HIV incidence during course of treatment
Problems during blood sampling were typically the reason
for missing laboratory tests. Due to the special situation
of the participants studied, the degree of completeness
obtained should be termed satisfactory in comparison
with experiences from other Swiss studies.
HIV Departures during each Laboratory data missing
negative patients six-month period or not in during each six-month Incidence rate
Time frame (without md) New infections treatment long enough testing phase (md) %
Entry
6 months
12 months
18 months
24 months
30 months
761
557
407
226
138
60
5
4
2
0
0
71
193
219
90
107
128
81
41
39
12
RRT7-30/T1-6 = 0.81 (0.25-2.63) n.s. (chi-square test)
Table 4 Hepatitis B incidence during course of treatment
HBV Departures during each Laboratory data missing
negative patients six-month period or not in during each six-month Incidence rate
Time frame (without md) New infections treatment long enough testing phase (md) %
28
55
66
19
23
RRT7-3o/Ti-« = 0.60 (0.26-1.35) p=0.21 (chi-square test).
Entry
6 months
12 months
18 months
24 months
30 months
229
117
74
37
23
8
13
6
1
1
1
71
53
23
17
10
8
3
4
Table 5 Hepatitis C incidence during course of treatment
HCV Departures during each Laboratory data missing
negative patients six-month period or not in during each six-month Incidence rate
Time frame (without md) New infections treatment long enough testing phase (md) %
12
39
33
18
4
Entry
6 months
12 months
18 months
24 months
30 months
153
108
74
43
26
13
12
3
2
1
1
1
21
13
9
7
0
10
4
4
4
RR T7-30 / T,_6 = 0.43 (0.17-1.06) p=0.06 (chi-square test).
HIV and hepatitis virus infections
At study entry we observed in this population a high
seroprevalence for hepatitis B (73%) and hepatitis C
(82%). In 1991 a prevalence of 57% for hepatitis B and
62% for hepatitis C was found at Zurich's Platzspitz.19 The
observed HIV seroprevalence (15%) was higher than
reported from other therapy programmes in Switzerland
with figures between 4 and 5%. • These differences
were in part expected as PROVE participants had a long
average duration of drug use and, seen in this and in other
studies, increasing duration of drug use is associated with
increasing seroprevalence for all three infections (HIV,
HBV, HCV). Yet, the fact that after 2-4 years of drug use
HBV and HCV seroprevalence already approach 50% is
evidence of a continuing risk of HBV and HCV infection
in the mid-1990s.
Accordingly, during the first months of treatment a hepa-
titis B and C risk of about 10% was observed. A halving
of the risks of a hepatitis infection occurred after the first
six months. The risk reduction coincided with a decrease
in general risk behaviour over the treatment time.
For example, a substantial decline in consumption of
illegal heroin was observed for the first months of treat-
ment.12 After 18 months of continued participation in
the programme, 74% of patients reported no illegal heroin
consumption, and the rate of cocaine abstinence in-
creased from 15% at entry to 41%. At admission 16% of
the patients reported sharing needles with others during
the previous six months. During the course of treatment,
less than 5% of patients indicated needle sharing. Signi-
ficant declines in visits to the drug scene and illegal
income were also observed.22
When interpreting the HBV and HCV risk during the
first six months one has to be aware of the window phase
of newly infected individuals, resulting in positive anti-
body tests several weeks after actual time of infection.23
Table 6 Comparison of social situation on admission of patients
with and without new infections during treatment
Gender
Male
Female
Duration of heroin
use
2-4 years
5-9 years
10-15 years
>15 years
Cocaine use
No consumption
Occasional
Almost daily
Criminal behaviour
Illegal income
a- Phi/Cramer's V test
Non-
seroconverters
in treatment
n=985
%
70
30
10
39
29
22
25
45
28
50
Seroconverters
in treatment
n=50
%
66
34
24
36
24
16
12
42
46
73
p-valued
n.s.
<0.05
<0.05
<0.01
Therefore the risk after HBV and HCV seroconversion
observed between study entry and follow-up at six months
can be considered to reflect in part risk of infection before
treatment started. The stated risk for HBV and HCV
seroconversion after follow-up at six months can then be
considered to reflect the risk of infection under the treat-
ment situation. It is noteworthy that, as mentioned, the
risk reduction after six months is in agreement with
self-reported reduction in risk behaviour during treat-
ment. However, a selection effect caused by premature
departures of high-risk individuals cannot be ruled out
completely. Yet the predictors found for premature
departures from treatment (e.g. long opiate addiction,
AIDS-related illnesses) provided no evidence of such
an effect.12'2'* The risk reduction observed for hepatitis B
and C was not found for HIV infections. However,
the small number of cases permits no conclusive inter-
pretation.
In conclusion, participants entering the Swiss medically
controlled prescription of. narcotics programme
(PROVE) during 1994 to 1996 had a high seroprevalence
for HIV, HBV, and HCV infection at entry and contin-
ued to have a substantial risk of infection. However,
during the course of treatment the risk of HBV and HCV
was halved for patients remaining in treatment. The
observed reduction in new infections parallel to the de-
cline in risk behaviour of the cohort group treated permits
the assumption of a favourable effect of heroin-assisted
treatment on infection risk. This decline in the incidence
rate of HBV and HCV occurred during the first months
of treatment. Then the incidence rate remains stabilized
at this lower level. This suggests a rapidly appearing effect
of treatment. Clinical control group trials would be
desirable for further analyses; however, these are very
difficult to carry out with patients addicted to drugs.
The high prevalence and incidence rates in treatment for
hepatitis B/C and HIV also show that additional efforts
are needed in this area. Successful prevention of these
infections is not easy to achieve. • Future interventions
should pay special attention to young and poorly
integrated patients.
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